评价LD002注射液单药治疗晚期/转移性恶性实体瘤或非霍奇金淋巴瘤受试者的安全性和耐受性，以评估最大耐受剂量（MTD）。为LD002注射液后续临床试验的推荐给药剂量和给药方案提供依据评价LD002注射液单药治疗晚期/转移性恶性实体瘤或非霍奇金淋巴瘤受试者的药效学（PD）特征评价LD002注射液单药治疗晚期/转移性恶性实体瘤或非霍奇金淋巴瘤受试者的初步抗肿瘤疗效评价LD002DS单抗的免疫原性探索PK和PD、疗效、安全性之间的相关性初步探索LD002注射液单药治疗晚期/转移性恶性实体瘤或非霍奇金淋巴瘤受试者的生物标记物

开始日期-

申办/合作机构

浙江蓝盾药业有限公司

100 项与 LD-002 相关的临床结果

登录后查看更多信息

100 项与 LD-002 相关的转化医学

登录后查看更多信息

100 项与 LD-002 相关的专利（医药）

登录后查看更多信息

项与 LD-002 相关的文献（医药）

2000-01-01·Artificial cells, blood substitutes, and immobilization biotechnology

A Rapid Interferent-Free Assay for the Determination of LD-1 in Biological Samples

Article

作者: G G Guilbault ; S Kelly ; C K O'Sullivan ; C P Cronin

A highly specific enzyme linked immunosorbent assay (ELISA) for the detection of lactate dehydrogenase-1 (LD-1) has been developed. A competition assay is described with polyclonal antibody to LD-1 passively adsorbed on an ELISA 96-well plate, with non-labelled and labelled LD-1 antigen competing. The LD-1 antigen is conjugated to alkaline phosphatase (ALP) using the one step glutaraldehyde method. A linear range of 10-4000 U/L was obtained, and cross-reactivity was only observed with LD-2. It was possible to eliminate this cross-reactivity by carrying out the final incubation step at 65 degrees C. The developed assay was applied to the analysis of spiked serum and plasma samples and the recoveries obtained were acceptable.

1990-11-01·Clinical chemistry1区 · 医学

Inhibition of lactate dehydrogenase isoenzymes by sodium perchlorate evaluated

1区 · 医学

Article

作者: Sanders, G T ; van der Neut, E ; van Straalen, J P

Abstract:

We evaluated a method of measuring lactate dehydrogenase isoenzyme 1 (LD-1) selectively (Clin Chem 1987;33:991-2), in which all other LD isoenzymes were inhibited by adding sodium perchlorate to the reaction medium to a final concentration of 0.825 mol/L. In this study we used the different isoenzymes purified from human autopsy tissue and found that the originally published amount of inhibitor (a) increased the original LD-1 activity and (b) did not eliminate all enzyme activity of LD-2 and LD-3. Interference by LD-2 was further demonstrated. Thus we conclude that this method cannot be used for the selective determination of LD-1 because its results do not accurately reflect the original LD-1 activity.

100 项与 LD-002 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝癌	临床1期	中国	浙江蓝盾药业有限公司	2022-03-09
非小细胞肺癌	临床1期	中国	浙江蓝盾药业有限公司	2022-03-09
卵巢癌	临床1期	中国	浙江蓝盾药业有限公司	2022-03-09
复发性惰性非霍奇金淋巴瘤	临床1期	中国	浙江蓝盾药业有限公司	2022-03-09
难治性惰性非霍奇金淋巴瘤	临床1期	中国	浙江蓝盾药业有限公司	2022-03-09
头颈部鳞状细胞癌	临床1期	中国	浙江蓝盾药业有限公司	2022-03-09
胃癌	临床1期	中国	浙江蓝盾药业有限公司	2022-03-09